Singapore-headquartered biotech firm MiRXES has launched its initial public offering (IPO) in Hong Kong under the ticker 2629.HK, with the investment community closely watching its performance. The firm specializes in RNA-based diagnostics, including its flagship early cancer detection platform GASTROClear, which is already approved in Singapore and China. MiRXES has priced its IPO at the lower end of the expected range, offering an entry point for high-risk, high-reward investors seeking exposure to next-gen diagnostic technologies.
According to analysis reviewed from market research sources, MiRXES posted 2023 revenue of HK$165 million with a gross margin of 44.5%. While still loss-making, with net losses widening from HK$123 million in 2022 to HK$170 million in 2023, the company’s investments in expanding commercial operations and product development are seen as a longer-term strategic play. The company plans to use IPO proceeds primarily for R&D, expanding its sales network in Asia-Pacific, and clinical trials for its pipeline diagnostics tools.
Notably, the firm’s ambition to scale beyond its current markets into the broader Asia-Pacific diagnostics segment aligns with anticipated regulatory tailwinds and rising demand for non-invasive cancer detection. While growth prospects remain promising, analysts warn that execution risk, high R&D burn, and competitive pressures from larger diagnostics firms remain key concerns. For short-term speculators, the IPO presents a volatile but potentially lucrative opportunity depending on post-listing sentiment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Readers are strongly advised to conduct their own due diligence and consult licensed financial advisors before making any investment decisions. The information presented is based on research sources deemed reliable but should not be construed as definitive guidance or endorsement.
